Literature DB >> 4246570

Anticataleptic actions of amantadine hydrochloride.

G Zetler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4246570     DOI: 10.1007/bf00997288

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmakol


× No keyword cloud information.
  4 in total

1.  Controlled trial of amantadine hydrochloride in Parkinson's disease.

Authors:  J D Parkes; D M Calver; K J Zilkha; R P Knill-Jones
Journal:  Lancet       Date:  1970-02-07       Impact factor: 79.321

2.  Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs.

Authors:  G Zetler
Journal:  Int J Neuropharmacol       Date:  1968-07

3.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

4.  The toxicologic and pharmacologic properties of amantadine hydrochloride.

Authors:  V G Vernier; J B Harmon; J M Stump; T E Lynes; J P Marvel; D H Smith
Journal:  Toxicol Appl Pharmacol       Date:  1969-11       Impact factor: 4.219

  4 in total
  5 in total

1.  The role of dopamine in pilocarpine-induced catalepsy.

Authors:  L Ahtee; I Kääriäinen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

2.  Studies on the central effects of bulbocapnine.

Authors:  A Loizzo; A S De Carolis; V G Longo
Journal:  Psychopharmacologia       Date:  1971

3.  Genetically determined predisposition to convulsions as the result of a generalized defect in the metabolism of catecholamines in the central nervous system.

Authors:  S A Dolina
Journal:  Neurosci Behav Physiol       Date:  1985 Nov-Dec

4.  Amantadine antagonism of oxotremorine effects.

Authors:  Y Eshel; A D Korczyn
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

Review 5.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.